Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open Label Prospective Single Center Drug Study Evaluating the Safety and Efficacy of (+)-Epicatechin in Subjects With Friedreich's Ataxia

NCT02660112 is registered in ClinicalTrials.gov with Ralitza Gavrilova as lead sponsor.

NCT NCT02660112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02660112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open Label Prospective Single Center Drug Study Evaluating the Safety and Efficacy of (+)-Epicatechin in Subjects With Friedreich's Ataxia
Lead sponsor
Ralitza Gavrilova
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2016
Completion date
December 30, 2018
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

friedreich's ataxia